Locoregional immunotherapy in cancer patients: review of clinical studies.
Many patients with invasive cancer have a compromised immune system. This immune dysfunction does appear to start at the site of the tumor. Locoregional immunotherapy is given to stimulate the immune system in order to kill tumor cells either indirectly via a specific or a non-specific way or directly via cell transfer therapy. Advantages to give this immunotherapy locoregionally in stead of systemically are a higher concentration of the immunomodulator at the site of the tumor, to attract or activate effector cells, and diminished toxicity. In this review we have summarised the clinical studies using loco-regional immunotherapy in patients with cancer. Only phase I and II studies were performed. Clinical responses were seen. No single locoregional treatment has become a standard therapy. Relatively few investigations were performed to estimate the influence on the locally effector mechanisms or immune dysfunction. In future clinical trials it is essential to get a better insight in these mechanisms.
van Herpen
C M
CM
Department of Medical Oncology, University Medical Centre Sint Radhoud, Nijmegen, The Netherlands. C.vanherpen@onco.azn.nl
De Mulder
P H
PH
D019264:Adoptive Transfer; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D005260:Female; D015316:Genetic Therapy; D005910:Glioma / Q000628:therapy; D006258:Head and Neck Neoplasms / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D009369:Neoplasms / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000628:therapy
D007376:Interleukin-2; D007372:Interferons